Oslo, Norway, 26 March, 2025

Reference  is made to  the stock exchange  notice published by  Zelluna ASA (the
"Company")  published on 26 March 2025 regarding the resolution by the Company's
board of directors to carry out a share capital increase of NOK 0.70 through the
issuance  of seven (7) new shares in the Company in order to achieve a desirable
ratio for the reverse share split.

The  Company has received the following notification  of a transaction made by a
close associate of a primary insider:

  * Radforsk Investeringsstiftelse, a close associate of chair of the board of
    directors and primary insider of the Company, Anders Tuv, has today
    subscribed for seven (7) new shares in the Company at a subscription price
    of NOK 2.60 (equal to the price per share in the recently completed business
    combination and private placement). Following this transaction, Radforsk
    Investeringsstiftelse hold 24,714,221 shares in Zelluna ASA.

The notification concerning the above subscription is attached hereto.

For further information, please contact:

Hans Vassg√•rd Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])
Phone: +47 482 48632

About Zelluna ASA
Zelluna's  mission is to deliver transformative  treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a  global scale.  The Company  aims to  do this  by combining  the most powerful
elements  of the  immune system  through pioneering  the development of "off the
shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The  TCR-NK  platform  offers  a  unique  mechanism  of action with broad cancer
detection  capability to overcome the diversity of tumours and will be used "off
the  shelf" to overcome scaling limitations  of current cell therapies. The lead
program  is a  world's first  MAGE-A4 targeting  "off the  shelf" TCR-NK for the
treatment  of various solid cancers; a pipeline of earlier products follows. The
Company  is  led  by  a  management  team  of  biotech  entrepreneurs  with deep
experience  in discovery through  to clinical development  of TCR and cell-based
therapies including marketed products.
